Amgen’s most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $175.00 short put and a strike $165.00 long put offers a potential 10.86% return on risk over the next 37 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $175.00 by expiration. The full premium credit of $0.98 would be kept by the premium seller. The risk of $9.02 would be incurred if the stock dropped below the $165.00 long put strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Amgen is bullish.
The RSI indicator is at 67.8 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Amgen’s (AMGN) Prolia Gets Label Expansion Approval in Europe
Mon, 11 Jun 2018 13:57:01 +0000
Amgen (AMGN) announces approval for its regulatory application seeking label expansion for Prolia in Europe.
Allergan oral migraine drug succeeds in study
Mon, 11 Jun 2018 13:14:18 +0000
Allergan Plc said on Monday its oral migraine drug met the main goal across all doses in a study, with a statistically significant reduction in monthly headache days in patients with episodic migraine. The treatment, atogepant, belongs to a class of migraine drugs also being developed by Eli Lilly and Alder Biopharmaceuticals that target a protein associated with pain signaling called calcitonin gene-related peptide (CGRP). Last month, the U.S. Food and Drug Administration approved Amgen Inc’s CGRP treatment Aimovig, which is self injected monthly and will have a list price of $6,900 a year, or $575 a month.
FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS® (carfilzomib) Label
Mon, 11 Jun 2018 13:00:00 +0000
THOUSAND OAKS, Calif., June 11, 2018 /PRNewswire/ — Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to add the positive overall survival (OS) data from the Phase 3 ASPIRE trial to the U.S. Prescribing Information for KYPROLIS® (carfilzomib).
/C O R R E C T I O N — Amgen/
Sat, 09 Jun 2018 00:23:00 +0000
In the news release, Amgen To Present At The Goldman Sachs 39th Annual Global Healthcare Conference, issued 07-Jun-2018 by Amgen over PR Newswire, we are advised by the company that the 1st paragraph, …
European Commission Approves Prolia® (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
Fri, 08 Jun 2018 13:00:00 +0000
“We are pleased that today’s EC approval provides physicians with a new treatment option for bone loss associated with the use of glucocorticoid medications,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. “Long-term glucocorticoid therapy is associated with a rapid and early decline in bone mineral density and increase in fracture risk,” said Professor Dr. Willem F. Lems, researcher and rheumatologist, VU University Medical Centre, Amsterdam.
Follow Us on Facebook